Neuropeptide Y overexpression using recombinant adenoassociated viral vectors Authors
Theme 3: Gene Therapy
Cite this article as: Noé, F., Frasca, A., Balducci, C. et al. Neurotherapeutics (2009) 6: 300. doi:10.1016/j.nurt.2009.01.012 Summary
Gene therapy may represent a promising alternative treatment of epileptic patients who are resistant to conventional anti-epileptic drugs. Among the various approaches for the application of gene therapy in the treatment of CNS disorders, recombinant adeno-associated viral (AAV) vectors have been most widely used. Preclinical studies using a selection of “therapeutic” genes injected into the rodent brain to correct the compromised balance between inhibitory and excitatory transmission in epilepsy, showed significant reduction of seizures and inhibition of epileptogenesis. In particular, transduction of neuropeptide genes, such as galanin and neuropeptide Y (NPY) in specific brain areas in experimental models of seizures resulted in significant anticonvulsant effects. Recent findings showed a long-lasting NPY over-expression in the rat hippocampus by local application of recombinant AAV vectors associated with reduced generalization of seizures, delayed kindling epileptogenesis, and strong reduction of chronic spontaneous seizures. These results establish a proof-of-principle evidence of the efficacy of gene therapy as anticonvulsant treatment. Additional investigations are required to address safety concerns and possible side effects in more detail.
Key Words Adeno-associated viral vectors anticonvulsant gene therapy in epilepsy neuropeptides temporal lobe epilepsy Download to read the full article text References
Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5: 553–564.
Foldvary N, Bingaman WE, Wyllie E. Surgical treatment of epilepsy. Neurol Clin 2001;19: 491–515.
Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet 2006;367: 1087–1100.
Perucca E. Pharmacoresistance in epilepsy: how should it be defined? CNS Drugs 1998;10: 171–179.
Kaplitt MG, During MJ. Gene therapy in the central nervous system. From bench to bedside, 1st ed. San Diego, CA: Elsevier Inc., 2006.
Haberman R, Criswell H, Snowdy S, et al. Therapeutic liabilities of in vivo viral vector tropism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity. Mol Ther 2002; 6: 495–500.
Raol YH, Lund IV, Bandyopadhyay S, et al. Enhancing GABA(A) receptor alpha 1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. J Neurosci 2006;26: 11342–11346.
Mazarati AM. Galanin and galanin receptors in epilepsy. Neuropeptides 2004;38: 331–343.
Noé F, Nissinen J, Pitkanen A, et al. Gene therapy in epilepsy: the focus on NPY. Peptides 2007;28: 377–383.
Lin EJ, Richichi C, Young D, Baer K, Vezzani A, During MJ. Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur J Neurosci 2003; 18: 2087–2092.
Foti S, Haberman RP, Samulski RJ, McCown TJ. Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo. Gene Ther 2007; 14: 1534–1536.
de Lanerolle NC, Kim JH, Robbins RJ, Spencer DD. Hippocampal intemeuron loss and plasticity in human temporal lobe epilepsy. Brain Res 1989;495: 387–395.
Vezzani A, Sperk G, Colmers WF. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci 1999;22: 25–30.
Furtinger S, Pirker S, Czech T, Baumgartner C, Ransmayr G, Sperk G. Plasticity of Y1 and Y2 receptors and neuropeptide Y fibers in patients with temporal lobe epilepsy. J Neurosci 2001;21: 5804–5812.
Patrylo PR, van den Pol AN, Spencer DD, Williamson A. NPY inhibits glutamatergic excitation in the epileptic human dentate gyrus. J Neurophysiol 1999;82: 478–483.
Baraban SC, Hollopeter G, Erickson JC, Schwartzkroin PA, Palmiter RD. Knock-out mice reveal a critical antiepileptic role for neuropeptide Y. J Neurosci 1997;17: 8927–8936.
El Bahh B, Balosso S, Hamilton T, et al. The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y2 and not Y5 receptors. Eur J Neurosci 2005;22: 1417–1430.
Colmers WF, Lukowiak K, Pittman QJ. Neuropeptide Y action in the rat hippocampal slice: site and mechanism of presynaptic inhibition. J Neurosci 1988;8: 3827–3837.
Greber S, Schwarzer C, Sperk G. Neuropeptide Y inhibits potassium-stimulated glutamate release through Y2 receptors in rat hippocampal slices in vitro. Br J Pharmacol 1994;113: 737–740.
Richichi C, Lin EJ, Stefanin D, et al. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J Neurosci 2004; 24: 3051–3059.
Noé F, Pool AH, Nissinen J, et al. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 2008;131: 1506–1515.
Pheng LH, Dumont Y, Founder A, Chabot JG, Beaudet A, Quirion R. Agonist- and antagonist-induced sequestration/intemalization of neuropeptide Y Y1 receptors in HEK293 cells. Br J Pharmacol 2003;139: 695–704.
Sorensen AT, Nikitidou L, Ledri M, et al. Hippocampal NPY gene transfer attenuates seizures without affecting epilepsy-induced impairment of LTP. Exp Neurol 2009;215: 328–333.
Holmes GL, Ben-Ari Y. Seizing hold of seizures (News and Views). Nat Med 2003;9: 994–996.
van Vliet EA, van Schaik R, Edelbroek PM, et al. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006;47: 672–680.
Danger JM, Tonon MC, Jenks BG, et al. Neuropeptide Y: localization in the central nervous system and neuroendocrine functions. Fundam Clin Pharmacol 1990;4: 307–340.
Hokfelt T, Broberger C, Zhang X, et al. Neuropeptide Y: some viewpoints on a multifaceted peptide in the normal and diseased nervous system. Brain Res Brain Res Rev 1998;26: 154–166.
CrossRef PubMed Copyright information
© The American Society for Experimental NeuroTherapeutics, Inc. 2009